Advertisement

Der physiologische Östrogenmetabolit 2-Methoxyestradiol induziert tumorspezifische Apoptose bei Zellen humaner hepatozellulärer Karzinome und führt zu Tumorhemmung in vivo

  • S. Scheunert
  • A. K. Nüssler
  • A. Rüggeberg
  • M. G. Bachem
  • A. R. Müller
  • K. P. Platz
  • H. Gerlach
  • P. Neuhaus
  • Guido Schumacher
Conference paper
Part of the Deutsche Gesellschaft für Chirurgie book series (DTGESCHIR, volume 31)

Abstract

Surgery remains the only treatment option with a potential cure for hepatocellular carcinoma. Thus, novel treatment options need to be investigated. 2-Methoxyestradiol (2-ME), a physiological metabolite of estrogen, has been shown to induce apoptosis and to reduce tumor growth in various different tumors. We examined the efficiency of 2-ME in tumor growth inhibition in human hepatoma cell lines. Proliferation assays, staining for apoptosis, and FACS analysis were performed. A subcutaneous tumor model in nude mice was used to assess the in vivo efficacy of 2-ME. We found a growth inhibition from 90% to 98% in all cells after treatment with 2 μM 2-ME for 5 days. Growth inhibition appeared to be caused by induction of apoptosis as shown by specific staining in all cell lines after 2 days of treatment. In contrast, no induetion of apoptosis was seen in normal hepatocytes. 2-ME treated mice showed a 45% lower average tumor volume when compared to non treated control mice. Three out of 10 mice in the 2-ME treated group had no tumor, whereas all control mice carried measurable tumors. Our data show that 2-ME is effective in the treatment of human hepatoma cells, which may be tumor specific.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Mukhopadhyay T, Roth JA. (1998) Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. Oncogene 17: 241 -6PubMedCrossRefGoogle Scholar
  2. 2.
    Schumacher G, Kataoka M, Roth JA, Mukhopadhyay T. (1999) Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 5: 493 - 9PubMedGoogle Scholar
  3. 3.
    McCormick DL, Johnson WD, Pribluda VS, Green SJ, Tomaszewski JE, Smith AC. (2000) Preclinical development of 2-methoxyestradiol [Abstract] Proc Am Assoc Cancer Res 41: 2080: 328Google Scholar
  4. 4.
    Schumacher G, Neuhaus R (2001) The physiological estrogen metabolite 2-Methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol 127: 405–410PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • S. Scheunert
    • 1
  • A. K. Nüssler
    • 1
  • A. Rüggeberg
    • 2
  • M. G. Bachem
    • 3
  • A. R. Müller
    • 1
  • K. P. Platz
    • 1
  • H. Gerlach
    • 1
  • P. Neuhaus
    • 1
  • Guido Schumacher
    • 1
    • 4
  1. 1.Viszeral- und TransplantationschirurgieKlinik für AllgemeinGermany
  2. 2.Klinik für Anästhesie, Charité, Virchow KlinikumHumboldt Universität BerlinGermany
  3. 3.Abteilung für Klinische ChemieUniversität UlmGermany
  4. 4.Klinik fur Allgemein-, Viszeral- und Transplantationschirurgie, Charité, Campus Virchow KlinikumHumboldt UniversitätBerlinGermany

Personalised recommendations